We are particularly pleased that Spiro PD's telemedicine design feature is such a help to people who, for a variety of reasons, simply can’t visit their doctors easily or regularly.
Allentown, PA (PRWEB) September 25, 2012
People with respiratory conditions who are physically challenged or live in remote areas may have difficulty visiting their doctors on a regular basis. Now, with its advanced telemedicine innovations, Spiro PD Personal Spirometer helps improve patient and doctor communication.
Spiro PD empowers patients to quickly and easily upload and send their lung function data to their doctor to determine the person’s lung health and need for any treatment changes. Patients and doctors can conveniently choose from a variety of reports, and choose to show reports over the last 7, 14, or 30 days. They can also select Custom reports, which allows them to pick test, lung function trend, spirometry loop, and medication history start and end dates.
Patients can also email results to their doctors. And because Spiro PD is lightweight and portable, patients can even bring it to their doctor's office to review results.
Spiro PD is the world’s first truly personal spirometer. It allows people with lung diseases – asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, cystic fibrosis (CF), and lung transplants – to easily and accurately monitor their breathing any time and anywhere: at home, at work, at school, at play, or while traveling.
Says Wayne Meng, Founder, Chief Executive Officer, and President of PMD Healthcare, the maker of Spiro PD, “Communication between patients and doctors is key to effectively treating lung diseases. That’s why telemedicine is becoming increasingly important in this area. We are particularly pleased that this design feature is such a help to people who, for a variety of reasons, simply can’t visit their doctors easily or regularly. We believe Spiro PD truly helps people with lung diseases better manage their condition – and improve their quality of life.”
For more information about all the advantages that Spiro PD offers people with respiratory conditions, please visit http://www.SpiroPD.com.
About Spiro PD
“Spiro" stands for spirometer, a device used to measure air entering and leaving the lungs; "PD" stands for personal device. Spiro PD is the first personal spirometer that enables people with lung diseases – asthma, COPD, CF, and lung transplants – to easily and accurately monitor their breathing anytime and anywhere.
Spiro PD tracks lung function trends to help patients anticipate and prevent exacerbations and asthma attacks, which helps reduce expensive emergency room visits and hospital stays. According to a study of cystic fibrosis patients at Johns Hopkins University, home spirometry detected exacerbations 16 days before patients felt symptoms and sought medical care.1
Spiro PD enhances medication adherence. The medication alarm helps patients remember to take their medicine. The medication history provides a time stamp to show doctors that patients have been following their therapy.
Spiro PD also allows patients to set alarms reminding them to perform spirometry tests and do breathing exercises. Plus, patients can quickly upload data to their computer and share it with their doctor.
Spiro PD is cleared by the FDA for home use by the patient to test lung function in children, adolescents, and adults. Many insurance companies cover the cost of Spiro PD.
Spiro PD meets American Thoracic Society (ATS) and European Respiratory Society (ERS) standards. Spiro PD is also certified with the CE mark for the European Union (EU).
For more information, visit http://www.SpiroPD.com.
About PMD Healthcare, Inc.
PMD Healthcare, manufacturer of Spiro PD, is dedicated to creating innovative, easy-to-use, portable, and affordable personal medical devices that empower people worldwide to improve their healthcare and quality of life. For more information about PMD Healthcare and Spiro PD, please visit http://www.SpiroPD.com.
1. West NE, Boyle MP, Mogayzel PJ, Riekert KA, Lechtzin N. The ability of home spirometry and symptom monitoring to predict exacerbations in cystic fibrosis. Pediatric Pulmonology 2009; Vol. 34, S32 “Poster Session Abstract” poster 376.